BACKGROUND: Low levels of selenium have been associated with increased risk of prostate cancer (PCa). Selenoprotein P is the most abundant selenoprotein in serum and delivers ten selenocysteine residues to tissues. Variation in the selenoprotein P gene (SEPP1) may influence PCa development or modify the effects of selenium. We examined the association of SEPP1 single nucleotide polymorphisms (SNPs) with PCa risk and survival, and tested for interactions. METHODS: The Physicians' Health Study (PHS) is a prospective cohort of 22,071 US physicians; we utilized a nested case-control study of 1,352 PCa cases and 1,382 controls. We assessed four SNPs capturing common variation within the SEPP1 locus. In a subset of men (n = 80), we evaluated SEPP1 mRNA expression in tumors. RESULTS: Two SNPs were significantly associated with PCa risk. For rs11959466, each T allele increased risk (odds ratio (OR) = 1.31; 95% confidence interval (CI): 1.02,1.69; P(trend) = 0.03). For rs13168440, the rare homozygote genotype decreased risk compared to the common homozygote (OR = 0.56, 95% CI: 0.33, 0.96). Moreover, there was a significant interaction of rs13168440 with plasma selenium; increasing selenium levels were associated with decreased PCa risk only among men with the minor allele (P(interaction) = 0.01). SEPP1 expression was significantly lower in men with lethal PCa than long-term survivors. CONCLUSIONS: SEPP1 genetic variation was associated with PCa incidence; replication of these results in an independent dataset is necessary. These findings further support a causal link between selenium and PCa, and suggest that the effect of selenium may differ by genetics.
BACKGROUND: Low levels of selenium have been associated with increased risk of prostate cancer (PCa). Selenoprotein P is the most abundant selenoprotein in serum and delivers ten selenocysteine residues to tissues. Variation in the selenoprotein P gene (SEPP1) may influence PCa development or modify the effects of selenium. We examined the association of SEPP1 single nucleotide polymorphisms (SNPs) with PCa risk and survival, and tested for interactions. METHODS: The Physicians' Health Study (PHS) is a prospective cohort of 22,071 US physicians; we utilized a nested case-control study of 1,352 PCa cases and 1,382 controls. We assessed four SNPs capturing common variation within the SEPP1 locus. In a subset of men (n = 80), we evaluated SEPP1 mRNA expression in tumors. RESULTS: Two SNPs were significantly associated with PCa risk. For rs11959466, each T allele increased risk (odds ratio (OR) = 1.31; 95% confidence interval (CI): 1.02,1.69; P(trend) = 0.03). For rs13168440, the rare homozygote genotype decreased risk compared to the common homozygote (OR = 0.56, 95% CI: 0.33, 0.96). Moreover, there was a significant interaction of rs13168440 with plasma selenium; increasing selenium levels were associated with decreased PCa risk only among men with the minor allele (P(interaction) = 0.01). SEPP1 expression was significantly lower in men with lethal PCa than long-term survivors. CONCLUSIONS:SEPP1 genetic variation was associated with PCa incidence; replication of these results in an independent dataset is necessary. These findings further support a causal link between selenium and PCa, and suggest that the effect of selenium may differ by genetics.
Authors: Kathryn L Penney; Fredrick R Schumacher; Haojie Li; Peter Kraft; J Steven Morris; Tobias Kurth; Lorelei A Mucci; David J Hunter; Philip W Kantoff; Meir J Stampfer; Jing Ma Journal: Cancer Prev Res (Phila) Date: 2010-04-27
Authors: Alfonso Calvo; Nianqing Xiao; Jason Kang; Carolyn J M Best; Isabel Leiva; Michael R Emmert-Buck; Cheryl Jorcyk; Jeffrey E Green Journal: Cancer Res Date: 2002-09-15 Impact factor: 12.701
Authors: Catherine Méplan; Fergus Nicol; Brian T Burtle; Lynne K Crosley; John R Arthur; John C Mathers; John E Hesketh Journal: Antioxid Redox Signal Date: 2009-11 Impact factor: 8.401
Authors: A J Duffield-Lillico; B L Dalkin; M E Reid; B W Turnbull; E H Slate; E T Jacobs; J R Marshall; L C Clark Journal: BJU Int Date: 2003-05 Impact factor: 5.588
Authors: Haojie Li; Meir J Stampfer; Edward L Giovannucci; J Steven Morris; Walter C Willett; J Michael Gaziano; Jing Ma Journal: J Natl Cancer Inst Date: 2004-05-05 Impact factor: 13.506
Authors: Philip W Kantoff; Lorelei A Mucci; June M Chan; Amy K Darke; Kathryn L Penney; Catherine M Tangen; Phyllis J Goodman; Gwo-Shu Mary Lee; Tong Sun; Sam Peisch; Alex M Tinianow; James M Rae; Eric A Klein; Ian M Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-06 Impact factor: 4.254
Authors: Jacklyn N Hellwege; Nicholette D Palmer; Julie T Ziegler; Carl D Langefeld; Carlos Lorenzo; Jill M Norris; Toshinari Takamura; Donald W Bowden Journal: Gene Date: 2013-10-24 Impact factor: 3.688
Authors: Hiten D Mistry; Carolyn A Gill; Lesia O Kurlak; Paul T Seed; John E Hesketh; Catherine Méplan; Lutz Schomburg; Lucy C Chappell; Linda Morgan; Lucilla Poston Journal: Free Radic Biol Med Date: 2014-11-06 Impact factor: 7.376
Authors: Naomi E Allen; Ruth C Travis; Paul N Appleby; Demetrius Albanes; Matt J Barnett; Amanda Black; H Bas Bueno-de-Mesquita; Mélanie Deschasaux; Pilar Galan; Gary E Goodman; Phyllis J Goodman; Marc J Gunter; Markku Heliövaara; Kathy J Helzlsouer; Brian E Henderson; Serge Hercberg; Paul Knekt; Laurence N Kolonel; Christina Lasheras; Jakob Linseisen; E Jeffrey Metter; Marian L Neuhouser; Anja Olsen; Valeria Pala; Elizabeth A Platz; Harri Rissanen; Mary E Reid; Jeannette M Schenk; Meir J Stampfer; Pär Stattin; Catherine M Tangen; Mathilde Touvier; Antonia Trichopoulou; Piet A van den Brandt; Timothy J Key Journal: J Natl Cancer Inst Date: 2016-07-06 Impact factor: 13.506
Authors: Andrew J Pellatt; Roger K Wolff; Esther M John; Gabriela Torres-Mejia; Lisa M Hines; Kathy B Baumgartner; Anna R Giuliano; Abbie Lundgreen; Martha L Slattery Journal: PLoS One Date: 2013-11-20 Impact factor: 3.240